19.12
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major publ…
Heavy metal drugs are effective antiprotozoal agents.
For example, sodium stibogluconate, or SSG, contains the heavy metal antimony and is widely used to treat Leishmania infections.
In the host, Leishmania lives inside macrophages.
Once administered, the drug enters the macrophages and then enters the parasite through aquaglyceroporin channels.
Thiol systems inside the parasite and the macrophages change SSG’s pentavalent antimony into the active trivalent form.
This active form blocks the enzyme trypanothione reductase, disrupting the parasite’s redox system.
Trivalent antimony also binds to free thiols and interferes with iron-sulfur cluster enzymes and zinc-binding proteases.
As a result, reactive oxygen species accumulate within the cell, damaging its proteins and membrane lipids.
The active drug then promotes the efflux of intracellular thiols, further weakening the parasite’s defense.
These effects ultimately result in the death of Leishmania and their removal from the host’s body.
View the full transcript and gain access to JoVE Core videos
Q1: How does sodium stibogluconate work against Leishmania infections?
Sodium stibogluconate (SSG) contains antimony and enters macrophages where Leishmania parasites live. Inside the parasite, thiol systems convert SSG's pentavalent antimony into the active trivalent form. This trivalent antimony blocks trypanothione reductase, disrupting the parasite's redox system and ultimately causing its death.
Q2: What is trypanothione reductase and why is it a selective drug target?
Trypanothione reductase (TR) is an enzyme that maintains redox balance in Leishmania by reducing oxidized trypanothione disulfide using NADPH. TR is absent in mammalian hosts, making it a selective target for chemotherapy. This selectivity allows antiprotozoal drugs to inhibit the parasite while minimizing harm to human cells.
Q3: How does trivalent antimony damage Leishmania cells?
Trivalent antimony blocks trypanothione reductase and binds to free thiols, interfering with iron-sulfur cluster enzymes and zinc-binding proteases. This causes reactive oxygen species to accumulate within the parasite cell, damaging proteins and membrane lipids. The drug also promotes efflux of intracellular thiols, further weakening the parasite's antioxidant defense.
Q4: What is the difference between Leishmania and mammalian redox metabolism?
Mammalian cells depend on the glutathione/glutathione reductase system for redox balance, while Leishmania uses a distinct thiol pathway based on trypanothione and trypanothione reductase. This trypanothione system acts as the main antioxidant defense in trypanosomatids, making it essential for parasite survival under oxidative stress.
Q5: How does antimonial drug activation occur inside host cells?
After administration, sodium stibogluconate enters macrophages through normal cellular uptake. The drug then enters the Leishmania parasite via aquaglyceroporin channels. Once inside, thiol systems in both the macrophage and parasite convert the pentavalent antimony into its active trivalent form, which can then inhibit trypanothione reductase.
Q6: What structural features of trypanothione reductase are important for drug binding?
Crystal structures reveal that trivalent antimony coordinates with specific amino acids: cysteine 52, cysteine 57, threonine 335, and histidine 461 from the opposing subunit of the trypanothione reductase dimer. This binding geometry disrupts the enzyme's ability to reduce oxidized trypanothione disulfide, blocking the parasite's redox cycle and causing cell death.
Q7: Why are heavy metal drugs like sodium stibogluconate effective antiprotozoal agents?
Heavy metal drugs are effective because they target parasite-specific biochemical pathways absent in mammalian hosts. Sodium stibogluconate's trivalent antimony form selectively inhibits trypanothione reductase, disrupting the parasite's unique redox system. This selectivity allows the drug to eliminate Leishmania while minimizing toxicity to human cells.